The Genetic Information and Family Testing (GIFT) Study
Launched by UNIVERSITY OF MICHIGAN ROGEL CANCER CENTER · Sep 20, 2022
Trial Information
Current as of August 20, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
GIFT features a web-based intervention that offers access to an online family communication program containing key facts about genetics, cancer risk, and the role of genetic testing and helps patients share health information with their first-and second-degree relatives, whom they can invite to join the study to receive education/support and access to low-cost genetic testing. Two design features of the intervention will be randomized and evaluated to determine the best approach for future scalability.
Those eligible will be offered enrollment into the Michigan-hosted intervention trial, a...
Gender
ALL
Eligibility criteria
- Inclusion criteria for the PICS survey are:
- • 1. diagnosed with any cancer at any stage in 2018-2019 and reported to the Georgia or California SEER registries
- • 2. Been found to carry a pathogenic variant (PV) in one of 27 cancer susceptibility genes (see Table 4) according to the Georgia California Genetic Testing Linkage Initiative dataset
- • 3. aged 18 or older
- • 4. alive at the time of selection as determined through linkage with Georgia and California vital statistics data.
- Additional eligibility criteria for Patient Trial Invitation will be evaluated from patient response to the PICS survey and will include patient report of:
- • 1. Receipt of genetic testing for cancer risk
- • 2. A positive test result (pathogenic variant; PV)
- Inclusion criteria for Relative Trial Invitation are assessed via patient report:
- • 1. first-degree (biological parent, sibling, or biological child) or second-degree (biological half-sibling, aunt, uncle, nephew, niece, grandparent, or grandchild) relative of a patient enrolled in the study;
- • 2. aged 18 or older;
- • 3. alive at the time of study invitation;
- • 4. relative lives in the United States or Canada (countries in which Color genetic testing is available, most people speak either English or Spanish, and test kit shipping costs are not exorbitant)
- Additional eligibility criteria for Relative Trial Enrollment will be evaluated from relative response to the relative eligibility screening survey (see Appendix C) and will include:
- • 1. confirmation from the relative that they have not received clinical genetic testing ordered by a doctor or genetic counselor within the past five years (proxy for having already been tested for the PV carried by the patient who invited them into the study);
- • 2. confirmation of age 18 or older;
- • 3. confirmation of first-degree (biological parent, sibling, or biological child) or second-degree (biological half-sibling, aunt, uncle, nephew, niece, grandparent, or grandchild) relation to the patient.
- • 4. confirmation of residence in United States or Canada
- • Exclusion Criteria
- Exclusion criteria for the PICS survey are:
- • 1) Age\<18
- Additional exclusion criteria for Patient Trial Invitation:
- • 1. Patients who do not report receipt of genetic testing
- • 2. Patients who do not report a positive genetic test result (PV)
- Exclusion criteria for Relative Trial Invitation are:
- • 1. Age\<18
- • 2. Relative does not live in the United States or Canada
- Additional exclusion criteria for Relative Trial Enrollment include relative report of:
- • 1. Age\<18;
- • 2. Receipt of genetic testing ordered by a doctor or genetic counselor within the past five years;
- • 3. Relationship to proband (inviting) patient other than first- or second-degree relative
- • 4. Residence in a country other than United States or Canada
About University Of Michigan Rogel Cancer Center
The University of Michigan Rogel Cancer Center is a leading academic research institution dedicated to advancing cancer treatment and prevention through innovative clinical trials. As a National Cancer Institute-designated Comprehensive Cancer Center, it combines cutting-edge research, state-of-the-art facilities, and a multidisciplinary team of experts to deliver personalized care and foster groundbreaking discoveries. The center's commitment to improving patient outcomes is reflected in its robust portfolio of clinical trials, which explore novel therapies and enhance understanding of cancer biology. Through collaboration with patients, researchers, and healthcare professionals, the Rogel Cancer Center aims to translate scientific insights into transformative therapies, ultimately contributing to the global fight against cancer.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Atlanta, Georgia, United States
Stanford, California, United States
Atlanta, Georgia, United States
Los Angeles, California, United States
Ann Arbor, Michigan, United States
Patients applied
Trial Officials
Steven Katz, MD
Principal Investigator
University of Michigan Rogel Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials